Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrogen Peroxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.46 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | CASP1 | P29466 | 1/20 | 0.77 |
| ▸ | CASP7 | P55210 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Peroxide SCHEMBL28372013 | 1.00 | CYP3A4 (0.77) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Benzene SCHEMBL28128773 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrogen Peroxide SCHEMBL5481727 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrogen Peroxide SCHEMBL296759 | 0.96 | CYP3A4 (0.83) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL3134351 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| SCHEMBL22003326 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL367451 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL269980 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Benzene SCHEMBL732720 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL9099015 | 0.92 | CYP3A4 (0.91) | CYP3A4ALOX15SMN1; SMN2CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252306-A1 | METHODS FOR INCREASING PROTEIN POLYETHYLENE GLYCOL (PEG) CONJUGATION | ANTICANCER, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8465734-B2 | Methods for increasing protein polyethylene glycol (PEG) conjugation | ANTICANCER, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| CN-1984924-B | Methods for increasing conjugation of protein and polyethylene glycol (PEG) | ANTICANCER INC | 2011-08-10 | — | — | CN | disclosed |
| US-20100331529-A1 | METHODS FOR INCREASING PROTEIN POLYETHYLENE GLYCOL (PEG) CONJUGATION | ANTICANCER, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1725583-B1 | METHODS FOR INCREASING PROTEIN POLYETHYLENE GLYCOL (PEG) CONJUGATION | ANTICANCER INC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7799549-B2 | Methods for increasing protein polyethylene glycol (PEG) conjugation | ANTICANCER, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080153740-A1 | Methods for increasing protein polyethylene glycol (PEG) conjugation | ANTICANCER, INC. | 2008-06-26 | — | — | US | disclosed |
| US-7329516-B2 | Methods for increasing protein polyethylene glycol (PEG) conjugation | ANTICANCER, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| CN-1984924-A | Methods for increasing conjugation of protein and polyethylene glycol (PEG) | ANTICANCER INC (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20070077257-A1 | Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications | EMINI EMILIO A | 2007-04-05 | — | — | US | disclosed |
| EP-1242124-A4 | POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040101957-A1 | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications | EMINI EMILIO A (US) | 2004-05-27 | — | — | US | disclosed |
| US-6733993-B2 | ADENOVIRAL VACCINES WHEN ADMINISTERED ALONE OR IN COMBINED MODALITY REGIME OFFER PROPHYLACTIC ADVANTAGE TO PREVIOUSLY UNINFECTED INDIVIDUALS AND/OR PROVIDE THERAPEUTIC EFFECT BY REDUCING VIRAL LOAD LEVELS WITHIN INFECTED INDIVIDUAL | MERCK & CO., INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040063653-A1 | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol | SHIVER JOHN W (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1320621-A2 | ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS | Merck & Co., Inc. (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002022080-A9 | ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS | MERCK & CO INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030044421-A1 | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications | MERCK SHARP & DOHME CORP. | 2003-03-06 | — | — | US | disclosed |
| EP-1242124-A1 | POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL | Merck & Co., Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002022080-A2 | ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001045748-A1 | POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL | MERCK & CO., INC. (US) | 2001-06-28 | — | — | WO | disclosed |